Radical concurrent chemoradiotherapy for esophageal carcinoma
10.3760/cma.j.issn.1673-422X.2016.01.014
- VernacularTitle:食管癌根治性同步放化疗
- Author:
Yongxuan LIU
;
Xiaoshan FENG
- Publication Type:Journal Article
- Keywords:
Esophageal neoplasms;
Radiotherapy;
Drug therapy;
Capecitabine
- From:
Journal of International Oncology
2016;43(1):49-52
- CountryChina
- Language:Chinese
-
Abstract:
In National Comprehensive Cancer Network guideline, patients with the clinical stages of Ⅰ B-ⅢA esophageal neoplasms should be given radical PF regimen (cisplatin + 5-fluorouracil) concurrent chemoradiotherapy.The majorization PF and radiation dosage are studied by some scholars in China and abroad, and the local control rate and survival rate are improved, adverse reaction is within a controllable range.In recent years, some new drugs such as capecitabine, paclitaxel, docetaxel, pemetrexed and carboplatin also show their advantages in radical concurrent chemoradiotherapy.
